Intellia Therapeutics, Inc. (NTLA) — Intelligence Dossier

1. Executive Summary

Intellia Therapeutics is a Cambridge, Massachusetts-based clinical-stage biotechnology company focused on developing potentially curative genome editing therapies using CRISPR/Cas9 and related technologies. It engineers both in vivo therapies delivered systemically via lipid nanoparticles and ex vivo therapies using engineered cells. Its lead programs include NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema.

2. Government Reliance & Contracts

• Federal reliance: Low to negligible as a direct contractor. Intellia is not a material federal prime or subcontractor; revenue comes from pharmaceutical partnerships, equity/debt financings, and potential future product sales, not government procurement.
• Agencies served: None material. It interacts with the FDA and EMA as regulators, not as customers. Indirect NIH or other federal research support may exist through academic collaborations or grants, but it is not core to operations.
• What they provide: No material goods or services to federal agencies. Government interaction is primarily regulatory: orphan drug, RMAT, and Fast Track designations.
• Key risk: Changes in NIH funding, FDA policy, or drug-pricing legislation could affect the broader biotech ecosystem, but direct contract revenue exposure is immaterial.

3. Moats & Key Technology

• Core technology: CRISPR/Cas9 genome editing, guide RNA design, lipid nanoparticle delivery, and scalable manufacturing. Intellia was the first to demonstrate systemic in vivo CRISPR editing in humans with NTLA-2001.
• IP moat: Licenses to foundational CRISPR/Cas9 intellectual property from Caribou Biosciences, the Broad Institute, and others, plus proprietary LNP and editing payloads. The CRISPR patent landscape is complex and litigated, but Intellia's licenses provide freedom to operate in key therapeutic fields.
• Regulatory moat: Orphan drug designations, RMAT, Fast Track, and clinical-stage know-how create barriers for competitors.
• Manufacturing/process moat: Scalable LNP formulation and CRISPR manufacturing capabilities.

4. Capital & Shadow Backers

• Public status: IPO on Nasdaq in May 2016 under NTLA, raising approximately $108 million. It is not a Form D company today; it files 10-K, 10-Q, and 8-K reports.
• Key backers: Regeneron Pharmaceuticals is a strategic partner and equity investor; Atlas Venture, OrbiMed, Fidelity, and other institutional investors participated in pre-IPO rounds. Caribou Biosciences is a foundational IP licensor and former affiliate.
• Funding strategy: Repeated public equity offerings, ATM programs, and partnership milestones. The Regeneron collaboration has included upfront payments and equity investments.
• Cash position: Pre-revenue, burn rate funded by cash reserves and partnership milestones; cash runway is a key metric.

5. Recent Catalysts

• Clinical: Phase 3 MAGNITUDE trial for NTLA-2001 in ATTR-CM; Phase 3 HAELO trial for NTLA-2002 in HAE; earlier Phase 1 data showed deep TTR reduction and HAE attack reduction.
• Regulatory: FDA RMAT, Orphan Drug, and Fast Track designations for lead programs.
• Partnerships: Regeneron collaboration expansions and potential milestone payments.
• SEC/legislative: 10-K/10-Q filings; Inflation Reduction Act drug-pricing provisions and CRISPR patent litigation are background risks and opportunities. No live 2025-2026 update was provided in the background data.